Ruud van Nistelrooy admits he was “hurt” at having to leave Manchester United last month. Van Nistelrooy returned to Old Trafford as Erik ten Hag’s assistant in the summer and had a four-game interim spell in charge following his compatriot’s sacking in October. He left the club in the wake of Ruben Amorim’s appointment but was only out of work for two weeks after being appointed Leicester’s new manager on a deal until 2027. The 48-year-old had a glittering playing career with United and was disappointed his return had to end so soon. “The moment I took over the interim job what I said was I’m here to help United and to stay to help United, and I meant it,” he said. “So I was disappointed, yeah, very much so, and it hurt I had to leave. “The only job I would take as an assistant was at United because of the bond that I have with the people in the club and the fans. “But in the end I got my head around it because I also understand the new manager. I’m in football long enough, and I’ve managed myself, that you can think of a situation, me being there, I understand. “I spoke to Ruben about it, fair enough to him, the conversation was grateful, man to man, person to person, manager to manager, and that helped a lot to move on and straightaway get into talks with new possibilities which of course lifted my spirits.” The Dutchman takes on a difficult job at the King Power Stadium as he is tasked with keeping Leicester in the Premier League. He inherits an influential dressing room, which has seen a number of managers come and go over the last few years. Ruud's here for his first press conference as our Manager 😃 pic.twitter.com/A4Juixvorb — Leicester City (@LCFC) December 2, 2024 Van Nistelrooy revealed he has done his due diligence and also let the players know as well. “It’s the only way you can work. It’s mutual respect. I also mentioned to the players yesterday that I looked at the squad and started to make phone calls about players, because in football everyone knows everyone,” he said. “With two or three phone calls you hear stories about 20 players and for me it was important that you hear there are good characters there. That’s important, that there are good people there. “I look at the players how they play. I obviously don’t know them but I got general information and the individuals that they are a good bunch of people. That was important for me to get in.”Conspiracy theorists seize on Wisconsin election error
Cineworld to close first site TOMORROW ahead of six closing for good
Short Interest in Forafric Global PLC (NASDAQ:AFRIW) Decreases By 47.6%West Virginia knocks off No. 3 Gonzaga in overtime
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. “The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. “Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company’s Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company’s common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient’s condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company’s Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the Company’s ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.com
76ers look for season-best 4th straight win vs. Blazers
NEW YORK (AP) — Right-hander Jonathan Loáisiga is guaranteed $5 million in his one-year contract from the New York Yankees as he returns from Tommy John surgery and could earn up to $10.5 million over two seasons. Loáisiga gets a $500,000 signing bonus and a $4.5 million salary next season as part of the agreement announced Saturday. New York has a $5 million team option for 2026 with no buyout. Loáisiga could earn $500,000 in performance bonuses in 2026: $100,000 apiece for 50 innings and each additional five through 70. Pitching coach Matt Blake said last week the 30-year-old right-hander could return in late April or May from Tommy John surgery last May 1. “I imagine him being one of the high-leverage guys,” Blake said. “Obviously, we got to take some time to get him right, make sure we don’t rush him into competition.” Loáisiga had a $2.5 million salary this year in his final season of arbitration eligibility and became a free agent. He made three relief appearances during the first seven days of the season, then went on the injured list because of a strained right flexor muscle, then had Tommy John surgery with team physician Dr. Christopher Ahmad. Loáisiga was limited to 17 games in 2023 by right elbow inflammation that sidelined him from the Yankees between April 5 and Aug. 8. He is 19-11 with a 3.44 ERA in 11 starts and 152 relief appearances over seven seasons, striking out 207 and walking 72 in 219 2/3 innings. Loáisiga averaged 97.8 mph with his sinker in 2023. AP MLB: https://apnews.com/hub/MLB
Bovine Colostrum Market Size & Trends To 2030 11-22-2024 06:13 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Prudent Markets Bovine Colostrum Market The Bovine Colostrum Market 2024 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Bovine Colostrum market. This report explores all the key factors affecting the growth of the global Bovine Colostrum market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis. The report concludes with the profiles of major players in the Bovine Colostrum market are: APS Biogroup, Biotaris B.V, Colostrum Biotec, Cure Nutraceutical, Deep Blue Health, Good Health NZ products, Immune Dynamics, Imu-Tek, Ingredia Nutritech, Pantheryx, Sterling Technology Discover Who You Really Compete Against In The Marketplace, Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/22296/ Bovine Colostrum Market Segmentation are: Type (Freeze Dried Powder and Spray Dried Power), By Distribution Channel (Drug stores, Supermarkets, Hypermarkets, Specialty Stores, and Online stores), By Application (Tablets, Powder, and Capsules), Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2019-2026 Prudent Markets offers the latest published report on Bovine Colostrum Market Analysis and Forecast from 2019 to 2026 delivering key insights and providing a competitive advantage to clients through a detailed report. Additionally, the report focuses on Bovine Colostrum industry key players, to define and analyze the sales volume, value, market share, market competitive landscape, and recent developments. Global Bovine Colostrum Market is estimated to reach $221.28 million by 2026; growing at a CAGR of 9.1% till 2026. About Bovine Colostrum Market Firstly, the report offers a basic overview of the industry including, definitions, classifications, applications, and industry chain scenario. The Bovine Colostrum industry analysis is provided for the global market including development history, segment analysis, major regional developments, and a thorough competitors evaluation. Secondly, growth policies and plans are reviewed as well as manufacturing processes and cost structures. This report also discusses supply and consumption figures, import/export data, cost, price, revenue and gross margins by prime regions such as the U.S. Europe, China, and Japan along with other key regions. Moreover, Bovine Colostrum Market proposes market trend analysis, drivers, and challenges by consumer behavior, and various marketing channels. Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs. Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/22296/ The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Bovine Colostrum Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market. Regional Analysis for Bovine Colostrum Market: • North America (the USA and Canada) • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) • Latin America (Brazil, Mexico and Rest of Latin America) • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa) TO KNOW MORE ABOUT COVID-19 IMPACT @ https://www.prudentmarkets.com/sample-request/22296/ Strategic Points Covered in Table of Content of Global Bovine Colostrum Market: Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Bovine Colostrum market Chapter 2: Exclusive Summary - the basic information of the Bovine Colostrum Market. Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Bovine Colostrum Chapter 4: Presenting the Bovine Colostrum Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis. Chapter 5: Displaying the by Type, End User and Region/Country Chapter 6: Evaluating the leading manufacturers of the Bovine Colostrum market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source Why should you purchase this report? -Prudent Markets provides the vital historical and analysis data of global Bovine Colostrum market. -The report provides the entire assessment of the future market and altering market scenario or behavior. -All the business decision could be backed through the several strategic business methodologies offered in the report. -An extra edge in the competitive market could be obtained from this elaborative research report -The report offers all the competitive landscape, growth drivers, applications, market dynamics, and other necessary details as well. For In-Depth Competitive Analysis - Purchase this Report now at a Complete Table of Contents (Single User License) @ https://www.prudentmarkets.com/checkout/?id=22296&license_type=su Free Customization on the basis of client requirements on Immediate purchase: 1- Free country-level breakdown of any 5 countries of your interest. 2- Competitive breakdown of segment revenue by market players. Customization of the Report: This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements. Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis. In conclusion, the Bovine Colostrum Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report. https://www.linkedin.com/pulse/equipment-agriculture-robot-market-2024-leading-player-bioqf/ https://www.linkedin.com/pulse/understanding-factors-influencing-polishing-3j8xc/ https://www.linkedin.com/pulse/analysis-protein-supplement-market-its-ejrkc/ https://www.linkedin.com/pulse/understanding-factors-influencing-advanced-ewcme/ https://www.linkedin.com/pulse/assessing-impact-growth-consumer-behavior-explosion-af56c/ Contact Us: Allan Carter Andheri, Maharashtra, 400102 USA/Canada(Toll Free): 1800-601-6071 Direct Line: +91 83560 50278 Mail: sales@prudentmarkets.com Web: www.prudentmarkets.com About Us: We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy. This release was published on openPR.
Citizens, Inc. Announces Filing of Form S-3 to Replace Expiring Shelf Registration Statement
Wearable Electrocardiogram (ECG) Monitors Market to Exhibit a Remarkable CAGR of 23.90% by 2029, Size, Share, Trends, Key Drivers, Demand, Opportunity Analysis and Competitive Outlook 12-02-2024 10:01 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Data Bridge Market Research Data Bridge Market Research analyses a global wearable electrocardiogram (ECG) monitors market growth in the forecast period 2022-2029. The expected CAGR of global wearable electrocardiogram (ECG) monitors market is tend to be around 23.9% in the mentioned forecast period. The market was valued at USD 2.13 billion in 2021, and it would grow upto USD 11.83 billion by 2029. An electrocardiograph (ECG) is a machine that records the surface potentials of the heart's electrical activity. Metal contacts called electrodes, which are fixed to various regions of the body, conduct the surface potentials of the device. Four limbs and the heart have electrodes linked to them. An ECG records the heart rate, rhythm, status of the conduction system and muscle tissue (heart attacks), and even the level of specific substances in the blood, such as potassium, as well as the medication's effect. Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-wearable-ecg-monitors-market Some of the major players operating in the wearable electrocardiogram (ecg) monitors market are Medtronic (U.S.), Koninklijke Philips N.V (Netherlands), OMRON Corporation (Japan), Dexcom, Inc (U.S.), Abbott (U.S.), Masimo (U.S.), General Electric Company (U.S.), Bio-Beat (U.S.),VitalConnect (U.S.), Preventice Solutions, Inc (U.S.), Contec Medical Systems Co Ltd. (Japan), ten3T Healthcare (India), Fitbit, Inc (U.S.), Huawei Technologies Co., Ltd (China) among others. Global Wearable Electrocardiogram (ECG) Monitors Market Share Analysis : The wearable electrocardiogram (ECG) monitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to wearable electrocardiogram (ECG) monitors market. Browse Trending Reports: https://dbmr064rs.blogspot.com/2024/11/potato-protein-market-analysis-supply.html https://dbmr03.blogspot.com/2024/11/ruminant-feed-mycotoxin-binders.html https://dbmr03.blogspot.com/2024/11/platelet-incubator-market-trends.html https://dbmr064rs.blogspot.com/2024/11/spondylosis-treatment-market-trends.html About Data Bridge Market Research: An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune. Contact Us: - Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC: +653 1251 1177 Email: - sopan.gedam@databridgemarketresearch.com This release was published on openPR.Credo Reports Second Quarter of Fiscal Year 2025 Financial Results
Drake wins 65-46 against BelmontTalphera CEO Vincent J. Angotti buys $3,649 in company stockAntonio Brown teases role in Donald Trump's administration - before swiftly deleting the post READ MORE: Steelers coach Mike Tomlin gives brutal response to Antonio Brown Follow DailyMail.com's politics live blog for all the latest news and updates By JAKE NISSE Published: 22:03 GMT, 27 November 2024 | Updated: 22:11 GMT, 27 November 2024 e-mail View comments Antonio Brown could be set for a role in Donald Trump 's next White House administration - if the often-unhinged ex-NFL star is to be believed. Brown, who has consistently ripped Democratic presidential candidate Kamala Harris , teased the possible gig this week after CNN anchor Kaitlan Collins was announced as the network's new Chief White House Correspondent. On Wednesday, the ex-Steelers receiver responded an X post that shared the Collins news and wrote, 'See you at the White House' with an eyeball emoji. Brown's reply was then swiftly deleted. The White House has not announced anything regarding a potential employment of Brown. Former Steelers wide receiver Antonio Brown has been an outspoken supporter of Donald Trump He teased a possible White House role on X on Wednesday before quickly deleting his post It's also possible that Brown - who previously posted pictures of Tom Brady 's ex-wife Gisele Bundchen hugging him on social media - could simply be making a lewd comment on Collins' appearance. However, he previously told DailyMail.com that he was serious about taking a job in Trump's administration if he was offered one. Brown claimed he would do whatever was needed to help Trump a success, from a job in the White House to becoming an elected representative. 'I'd be the man in the office,' he said, when asked what sort of job he would like to do. 'The House of Representatives or something.' Brown attended a Trump rally and led a voter registration drive at a tailgate party - both in Pittsburgh - before the 78-year-old was ultimately elected as president for a second time. At one point during the rally, Brown and former Steelers teammate Le'Veon Bell both appeared onstage next to Trump. While the election took place more than three weeks ago, Brown has continued to take aim at Vice President Harris. Brown previously appeared onstage at a rally alongside trump and ex-teammate Le'Veon Bell Former Steelers star Brown also led a voter registration drive at a tailgate party in Pittsburgh In a clip just under 30 seconds posted on the X account on Tuesday night for the Democratic party , an emotional Harris said in a seemingly unprompted clip: 'I just have to remind you, don't you ever let anybody take your power from you. Read More Antonio Brown and Clay Travis rip Kamala Harris over bizarre Thanksgiving message 'You have the same power that you did before November 5th. And you have the same purpose that you did. And you have the same ability to engage and inspire. 'So don't ever let anybody or any circumstance take your power from you.' Brown - like other conservative voices - questioned whether Harris was sober in the video. 'I swear to drunk I'm not God,' Brown wrote next to a screengrab of Harris looking especially emotional and bleary-eyed. Brown, a seven-time Pro Bowler in the NFL, last appeared on the field in January 2022 - when he ripped off his pads and jersey at MetLife Stadium in the middle of a game vs. the Jets and headed to the locker room. Donald Trump Pittsburgh Steelers Share or comment on this article: Antonio Brown teases role in Donald Trump's administration - before swiftly deleting the post e-mail Add comment
Duck Creek partners with Suncorp to deliver a suite of cloud-native, low-code core insurance delivery solutions